NCT06118463Not yet recruiting
Study on AUNIP as a Novel Tumor Marker for Cervical Cancer
Source: ClinicalTrials.gov · Last updated 9 Nov 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To detect the expression of AUNIP in cervical cancer serum, and to clarify its diagnostic and prognostic value.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 31 Oct 2023
- Start date
- 1 Jan 2024
- Primary completion date
- 1 Oct 2027
- Lead sponsor
- Lin Yuan
- Diseases
- Cervical cancer
- NCT number
- NCT06118463
What you commit to
- Study type: Observational
- Planned participants: 300
- From 1 Jan 2024 to the primary completion date, 1 Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- There are other lesions in the uterus and uterine adnexa
- Pregnant, lactating or menarche women
- Women who are undergoing human papillomavirus (HPV) vaccination
Who the study is looking for
- Study group inclusion criteria:
- Women aged 20-60
- There is a definite pathological diagnosis of cervical cancer
- Healthy control group:
- Women aged 20-60
- No tumors in the uterus or other parts of the body
- No inflammatory disease
- Blood routine and blood biochemical tests are normal
Age in the registry: 20 years to 60 years · Sex: Female · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.